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Abstract
In many clinical trials treatments need to be repeatedly applied as diseases relapse
frequently after remission over a long period of time (e.g., 35 weeks). Most research in
statistics focuses on the overall trial design, such as sample size and power calculation,
or on the data analysis after trials are completed. Little is done to improve the efficiency
of trial monitoring, such as early termination of trials due to futility. The challenge
faced in such trial monitoring is mostly caused by the need to properly model repeated
outcomes from patients. We propose a Bayesian trial monitoring scheme for clinical
trials with repeated and potentially cyclic binary outcomes. We construct a latent
Gaussian process (LGP) to model discrete longitudinal data in those trials. LGP
describes the underlying latent process that gives rise to the observed longitudinal
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binary outcomes. The posterior consistency property of the proposed model is studied.
Posterior inference is conducted with a hybrid Monte Carlo algorithm. Simulation
studies are conducted under various clinical scenarios, and a case study is reported
based on a real-life trial. Matlab program for implementing the interim monitoring
procedure is freely available at http://www.ma.utexas.edu/users/yxu.
KEY WORDS: Clinical Trial; Forecast; Hierarchical Model; Hybrid Monte Carlo;
Latent Variable; Longitudinal Data.
1 Introduction
1.1 Background
We consider Bayesian monitoring for clinical trials with longitudinal binary outcomes, such
as multiple disease remissions over time. This is an area that has received little attention
in the trial design field. Most work has focused on the overall design of the trial (Frison
and Pocock, 1992; Raudenbush and Liu, 2001; Galbraith et al., 2002; Hedeker et al., 1999),
such as sample size calculation and choice of followup time points, or methods for analyzing
data after trials are completed (Liang and Zeger, 1986; Hedeker and Gibbons, 2006). In
many trials, the primary outcome data for each subject are recurrent and cyclic based on a
longitudinal binary variable. For example, a data vector of interest could be binary values
observed on consecutive time points, and the vector values alternate between 1’s and 0’s.
This type of data arises from clinical trials in many therapeutic areas, such as auto-immune
diseases like multiple sclerosis or Schizophrenia (see Goldman et al., 2010 and references
therein). Typically, treatments need to be applied multiple times in hopes to slow down
disease progression. When multiple drugs are to be evaluated, it is challenging to quantify
and compare the efficacy of the drugs due to the temporal and periodic nature of disease
progression and treatment response. For example, when two drugs are compared in a clinical
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trial involving one new treatment and a standard treatment, therapeutic effects are usually
assessed by comparing the relapse rates of treatments within a time framework. However,
that strategy might not be ideal since a treatment with a slightly inflated relapse rate might
still be preferred if it allows patients to stay in disease remission for a longer period of time.
In this paper, we consider an important design issue for trials of the same nature. For
each patient, multiple responses to treatments and multiple disease relapses are expected.
One goal is to demonstrate that one treatment allows patients to stay in disease remis-
sion longer than the other, and a second goal is to predict future responses for individ-
ual patients based on observed outcomes. A typical patient response vector may look like
(1, 1, 0, 0, 1, 1, 1, 0, 0 · · · ) with binary outcomes at multiple time points, where “1” repre-
sents a response and “0” a nonresponse. In addition, each binary outcome is associated
with a time point at which the outcome is recorded. Therefore, the data is summarized
as {e(tk), k = 1, . . . , K} where e(tk) ∈ {0, 1} is binary. In Comi et al. (2012), a response
{e(tk) = 1} is defined as a combination of cognitive improvements assessed by psychiatric
tests. An important presumption that underpins this type of trial is that the unobserved
disease progression is a continuous process over time, although measurements of outcome
can only be taken at discrete time points, e.g., once a month. In other words, the observed
binary longitudinal outcomes are manifestations of latent continuous processes.
To model a latent process, Zeger et al. (1985) considered an extension of logistic re-
gression to binary longitudinal observations. However, their method was only applied to
stationary binary series. Czado and Song (2008) developed a state space mixed model for
binary longitudinal observations using the standard linear state-space formulation (Kalman,
1963). But the linear state-space models are limited and may not work well on the afore-
mentioned trials with nonlinear and cyclic responses. Hall et al. (2008) proposed a latent
Gaussian process model for sparse generalized longitudinal observations. They estimated
the mean function by smoothing the mean of all trajectories and covariance kernel by calcu-
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lating functional principle components as the eigenfunctions. While useful, their smoothing
technique must be applied to all observations collectively, not allowing random effects that
deviate from the population curve. More importantly, available models for longitudinal data
cannot accommodate all our needs for trial monitoring, which include 1) to model cyclic
binary responses, 2) to forecast future outcomes for each patient based on the cyclic pattern,
3) to compare population patterns between different conditions (treatment v.s. control), 4)
to reflect the underlying continuous disease progression mechanism. Also, to our knowledge,
there does not exist an adaptive monitoring scheme for trials with binary longitudinal out-
comes. For example, there are no existing statistical methods for terminating such trials
when the treatment arm is not effective as the control. To this end, we consider a latent
stochastic process with cyclic features to describe the relapsing nature of the disease. Specif-
ically, let aj(t) = µ(t) + τj(t) be a sum of the mean process µ(t) describing the treatment
effect over time, and a cyclic process τj(t) describing the subject-j-specific recurrent disease
progression. For example, the treatment effect µ(t) could be increasing over time due to
the continuous usage of the drug but τj(t), to be modeled as the latent Gaussian process,
could be cyclic mimicking the recurrent disease progression as a result of the battle between
the disease-causing antigens and the disease-fighting immune cells. We model the binary
outcome at a time point tk as an indicator ej(tk) = I{aj(tk) > ah} with a fixed and arbitrary
threshold value ah. This construction can be considered a stochastic-process version of the
latent probit model in Albert and Chib (1993). We defer the construction of aj(t) to Section
2.
1.2 Gaussian Process
Gaussian process (GP) has been frequently applied to research areas in finance, engineering,
cognitive research, and others. Examples of such applications include work in machine
learning (Rasmussen and Williams, 2006), neural networks (Neal, 1995), and batched data
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(Shi et al., 2007). Initially introduced in O’Hagan and Kingman (1978), GP priors have
also been used in Bayesian inference for regression and classification problems; see a review
by Williams (1998). GP models are considered nonparametric in curve fitting as they are
not dependent on any functions to describe the shapes of the curves. At the same time,
GP models are relatively easy to compute since they are based on multivariate Gaussian
distributions.
A Gaussian process is a stochastic process a(t), for which any n-finite variates an =
{a(t1), . . . , a(tn)}′ has a multivariate Gaussian distribution given by
P (an | µ,C) ∝ |C|− 12 exp
{
−1
2
(an − µ)′C−1(an − µ)
}
for any n and collection of input {t1, . . . , tn}. Vector µ is the mean vector with dimension
n and C represents the n× n covariance matrix, and is often parameterized as a covariance
function Cuv(tu, tv; Θ), where Θ is a set of hyperparameters. In other words, a Gaussian
process is one which every finite-dimensional joint distribution is multivariate Gaussian.
Since we are expressing the correlations between different points in the input space through
the covariance function, it is crucial to study the characteristics of the GP, such as its smooth
properties and differentiability (Abrahamsen, 1997).
1.3 Motivating Examples
The key idea of our proposed LGP is to model observed discrete longitudinal outcomes by
thresholding the latent variates that follow a GP prior. We consider two motivating examples.
The first example is a randomized, double-blind, placebo-controlled clinical trial aiming to
evaluate the efficacy and safety of a 200-mcg dose of a new drug (drug name masked for
copyright protection) in patients with systemic lupus erythematosus (SLE). We will refer to
this trial as the “lupus trial” hereinafter. SLE is a long-term auto-immune disease in which
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the body mistakenly attacks healthy organs, such as the skin and brain. There is no cure for
the disease, and immuno-therapies only reduce symptoms and must be applied frequently.
Patients respond to treatments quickly, typically within weeks, although the disease also
relapses quickly. A clinical response is based on the SLE responder index, which is defined
by a combination of four different cognitive test scores. In the presence of control, each
patient is randomized and followed for 35 weeks, during which time multiple relapses and
responses might be observed. The trial objective is to compare the response rates of the
new treatment and the control. It is desirable to terminate the trial early since the 35-week
follow-up time period is long; for example, whenever there is substantial evidence that the
new treatment is no better than the control, the trial should be stopped for both ethical and
financial considerations. The total sample size for the lupus trial is 200 patients, who are
randomized 1:1 between the two treatments.
A second similar example is a placebo-controlled trial of oral laquinimod for multiple
sclerosis (Comi et al., 2012). The efficacy and safety of laquinimod in patients with relapsing-
remitting multiple sclerosis were evaluated in a randomized, double-blind, phase III trial
with 1,106 patients randomly assigned in a 1:1 ratio to receive placebo or laquinimod. The
primary end point was whether or not the disease had relapsed during the study period.
An event was counted as a relapse if the patient’s symptoms were accompanied by objective
neurologic changes according to predefined criteria.
A common feature in both trials is that multiple responses and relapses are expected for
each patient during the follow-up period, and therefore simple monotonic parametric dose-
response models such as logistic regression are no longer suitable. The observed data for
each patient will be a binary vector e = (e1, e2, . . . , eK) for K time points. The indicators
are temporally correlated.
In Section 2, we present probability models and computational methods based on the
posterior distributions. In Section 3, we derive posterior consistency results. In Section 4,
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we propose inference for predicting future responses and introduce stopping rules as part of
the trial design. We examine the performance of LGP through extensive simulation studies
in Section 5. In Section 6, we report numerical results based on the lupus trial. Finally, we
conclude with a brief discussion in Section 7.
2 Probability Model
2.1 Latent Gaussian Process
In the aforementioned lupus trial, patients are randomized between two arms, with arm 1
being the standard control and arm 2 the new treatment. Multiple interim analyses are
proposed to monitor the progress of the trial and to compare the two treatments. At the
time of interim analysis, assume that N1 and N2 patients have been assigned to arms 1 and 2,
respectively (N1 = N2 if equal randomization). For each patient j in group i, we assume that
disease outcomes have been measured at Kij time points, denoted as tij = (t1, t2, . . . , tKij)
′.
Here a time point refers to the duration of follow-up. Let eij(tk) be the binary response at
time point tk, simplified as eijk. If the jth patient in group i responded at time tk, then
eijk = 1; otherwise, eijk = 0. Therefore, the observed data are tuple e
K = {eijk}, i =
1, 2; j = 1, 2, . . . , Ni; k = 1, 2, . . . , Kij.
Define a stochastic process
aij(t) = µi(t) + τij(t) (1)
where µi(t) is the mean process that describes the effects of drug i and τij(t) is a zero-mean
GP that induces temporal correlation within a patient.
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Denoting the latent variable aijk ≡ aij(tk), we assume eijk = I(aijk > ah), i.e.,
eijk =
 1 if aijk > ah0 otherwise ,
where ah is an arbitrary threshold and I(·) is the indicator function.
In (1), the choice of µi(t) depends on the underlying disease and drug mechanism. Based
on prior knowledge, for example, if we believe that the efficacy of a drug is increasing over
time, we could simply use a linear function µi(t) = βi0 + βi1t with a positive slope; if we
believe the efficacy increases first then decreases due to drug resistance, we could use a
quadratic function. To accommodate different shapes of response curves, we choose the
polynomial regression model to describe the drug mean effects over time, i.e.,
µi(t) = βi0 + βi1t+ · · ·+ βi,mitmi , (2)
where βi = (βi0, βi1, . . . , βi,mi)
′ are regression coefficients of time for each of the two treatment
arms (i = 1, 2). In practice, the degree mi of the polynomial is unknown, and we let
mi = {0, 1, . . . ,M} be a random variable taking integer values between 0 and a large number
M . It is important to allow (mi,βi) to vary for different arms i so that the drug effects can
be easily compared by posterior inference using these parameters. Also, we do not consider
nonparametric functions for modeling µi(t) to avoid potential identifiability issue in the
model since τij(t) is already nonparametric.
Note that βi describes the global response pattern of each arm i. For the dependence
across time within each patient j, we assume that τij(t) follows a zero-mean GP that induces
the cyclic correlation of aij(t). Let
τij(t) | Θ ∼ GP
(
0Kij ,C(tij; Θ)
)
, (3)
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where 0Kij is a Kij-dimension 0-vector, andC(tij; Θ) is a Kij×Kij covariance matrix indexed
by Θ.
Based on (1), (2) and (3), the proposed latent Gaussian process functional regression
model is given by
P (aK | β,m,Θ) ∝
2∏
i=1
Ni∏
j=1
|C(tij)|− 12 exp
{
−1
2
(aKij −Xijβi)′C(tij)−1(aKij −Xijβi)
}
, (4)
where aKij = (aij1, . . . , aijKij)
′, β = {βi}, m = {mi}, i = 1, 2 and the design matrix Xij of
the polynomial (2) is
Xij =

1 t1 · · · tmi1
1 t2 · · · tmi2
...
...
. . .
...
1 tKij · · · tmiKij

.
The covariance matrix C(tij) is usually parameterized to induce within-patient dependence
over time. The most popular parametrization (Williams, 1998) of the stationary covariance
function C(tij; Θ) is a Kij ×Kij matrix with the uv-th element Cuv defined by
Cuv(Θ) = θ
2
1 exp
{−r2(tu − tv)2}+ δuvJ2, u, v = 1, . . . , Kij. (5)
In (5) Θ = (θ1, r)
′, Cuv(Θ) is the covariance of the GP for time points tu and tv, δuv =
I(u = v), and J is the variance on the diagonal reflecting the amount of jitter (Bernardo
et al., 1999), which usually takes on a small value (e.g, J = 0.1). This construction of the
covariance matrix yields a strong correlation for observations at time points close to each
other and has been widely adopted (Williams, 1998).
However, if the system is recurrent, which is the case here for the lupus trial, formulation
(5) is not suitable since it is aperiodic. Instead, we should consider other forms of covariance
functions with periodicity. For example, a periodic model with known wavelength θ2 is given
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by
Cuv(Θ) = θ
2
1 exp
{
−r2 sin2(pi(tu − tv)
θ2
)
}
+ δuvJ
2, (6)
and Θ = (θ1, θ2, r)
′. This covariance function provides strong correlations not only for
adjacent time points but also for those separated from each other by a distance θ2 or its
multiplications. We will use (6) as the model for our trial applications. As an illustration,
Figure 1 shows some realizations of τij(t) with different covariance functions C. The real-
izations display some periodic patterns although their shapes can be quite different. This
implies that the class of GP models with covariance (6) is general and can describe curves
with a variety of different shapes.
Define the column vector aK = {aijk, i = 1, 2; j = 1, 2, . . . , Ni; k = 1, 2, . . . , Kij}′. The
likelihood function is given by
P (eK | aK) =
2∏
i=1
Ni∏
j=1
Kij∏
k=1
P (eijk | aijk)
=
2∏
i=1
Ni∏
j=1
Kij∏
k=1
{I(aijk > ah)I(eijk = 1) + I(aijk <= ah)I(eijk = 0)} .
(7)
As a summary, the hierarchical model factors as
P (eK ,aK ,m,β,Θ) ∝ P (eK | aK)︸ ︷︷ ︸
(7)
P (aK | β,m,Θ)︸ ︷︷ ︸
(4)
P (β |m)P (m)P (Θ), (8)
where m = (m1,m2)
′ and β = (β′1,β
′
2)
′. The first factor is the sampling model (7). The
second factor is the latent Gaussian process functional regression model (4). The remaining
factors are priors of m,β and (θ1, θ2, r). We assume a uniform prior on P (mi). For example,
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Figure 1: Three random samples drawn from the Gaussian process τij with four different
covariance matrices. The corresponding covariance is given below each plot. The decrease
in length scale from (a) to (b) produces more rapidly fluctuating functions. The periodic
properties of the covariance function in (c) and (d) can clearly be seen.
given a large integer M , P (mi) = 1/(M + 1) for mi = 0, 1, . . . ,M . We assume
βi ∼ Gaussian(µmi+10 , σ20Imi+1)
θ1 ∼ Gaussian(µ1, σ21), r ∼ Gaussian(µ2, σ22), θ2 ∼ Gaussian(µ3, σ23),
where µmi+10 is (mi+1)-dimension mean vector, and Imi+1 is an (mi+1)×(mi+1) dimension
identity matrix. We assume vague priors for βi, θ1, r, θ2 by imposing large values of variances
(σ20, σ
2
1, σ
2
2, σ
2
3).
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We will show that the LGP model in (8) possesses desirable theoretical and numerical
properties, such as consistency, the ability to forecast for individual patients and to stop
trials early.
2.2 MCMC Simulations
The most significant computational cost of implementing a GP model when dealing with a
vast number of time points is the inversion of the covariance matrix C. Such an inversion is
required to make any predictions and, most significantly, in Bayesian inference to evaluate
the gradient of the log posterior distribution over Θ in every Markov chain Monte Carlo
(MCMC) iteration.
We carry out posterior inference based on MCMC simulation. The proposed Gibbs
sampler proceeds by iterating over the following transition probabilities
P (aK | eK ,β,m,Θ), P (m | aK ,Θ), P (β | aK ,m,Θ), P (Θ | aK ,β,m).
We start by generating aK from their full conditional posterior distributions – truncated
Gaussian. Efficient ways to sample from truncated Gaussian can be found in Geweke
(1991); Liechty and Lu (2010); Pakman and Paninski (2013). Through a cycle of Gibbs
steps we also generate random draws of m, β and Θ. When updating m, we sample
from the full conditional posterior distributions, marginalized with respect to β (See Ap-
pendix A). Given m, sampling of β is straightforward because of the fixed dimensional-
ity and Gaussianity. This avoids the need for trans-dimensional MCMC. The challenging
step is to sample Θ, the full conditional of which is analytically intractable. However, we
can obtain the approximations using the most probable values such as Evidence maximiza-
tion (MacKay, 1992) or other non-Gibbs MCMC samplers. The most commonly used and
straightforward method is the random-walk Metropolis sampling, but Bernardo et al. (1999)
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argued that simple Metropolis algorithms were not efficient and therefore advocated for the
use of hybrid Monte Carlo (Duane et al., 1987). This idea was implemented by Barber
and Williams (1997) who analyzed classification problems and achieved better results us-
ing hybrid Monte Carlo compared to Metropolis algorithms. With the same motivation,
we propose a hybrid MCMC algorithm to sample the hyperparameters Θ in the covari-
ance function C(Θ). The idea behind hybrid MCMC is to augment the parameter space
and draw Metropolis proposals with improved samplers. Suppose we want to draw Monte
Carlo samples from a proposed density P (Θ) ∝ exp{−E(Θ)}, where Θ = (θ1, . . . , θn). In
physics terminology, Θ can be regarded as a position vector and E(Θ) the potential en-
ergy function. As a data augmentation step, we then introduce another set of variables
called “momentum variables”, w = {w1, w2, . . . , wn}, one wi for each θi, with a kinetic
energy function, P (w) = 1
ZK
exp(−K(w)) = (2pi)−n/2exp(−1
2
∑
iw
2
i ). The momentum vari-
ables are introduced to make random walks continue in a consistent direction until a region
of low probability is encountered. The total energy function, known as Hamiltonian, is
H(Θ,w) = E(Θ) + K(w) = E(Θ) + 1
2
∑
iw
2
i . The canonical distribution defined by this
energy function is P (Θ,w) = 1
ZH
exp{−H(Θ,w)} = P (Θ)P (w). Random samples of (Θ,w)
are jointly proposed by appropriate probabilities (see Appendix A for details). Samples from
the marginal distribution for Θ can be obtained by ignoring the values w. Specifically, we
use a discretized approximation called the leapfrog algorithm (Neal, 1997), details of which
are again described in Appendix A.
To summarize, the proposed MCMC algorithm includes a Gibbs sampler for aK , m, β
and a hybrid Monte Carlo algorithm for sampling Θ. The algorithm converges well with
an initial burn-in of 2,000 iterations and a total of 10,000 iterations with a lag of 10 in
our simulation studies. We conduct convergence diagnostics using R package coda and find
no evidence for convergence problems. Traceplots and empirical autocorrelation plots (not
shown) for the imputed parameters indicate a well mixing Markov chain.
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3 Posterior Consistency
We discuss theoretical properties of the LGP model and show that it is consistent as the
number of treated patients goes to infinity. For simplicity in the following discussion, we
only consider one treatment arm by dropping index i and use n to denote the number of
patients and Kj to denote the number of time points observed for patient j. The proposed
LGP model can be summarized as follows:
ejk = ej(tk) | p(tk) ∼ Bernoulli(p(tk)), k = 1, . . . , Kj, j = 1, . . . , n
p(t) = H (a(t)) ≡ Pr (a(t) > ah) , t ∈ [0, TE]
a(·) ∼ GP (µ(·), C(·, ·)), (9)
where observation times tk’s are irregularly spaced points for each patient and fixed in
advance on the compact set T = [0, TE] ⊂ R in which TE is the length of the trial, and
H is a known, strictly increasing, Lipschitz continuous cumulative function. Note that a(·)
is a Gaussian process parameterized by its mean function µ: T → R and its covariance
function C : T 2 → R, denoted by GP (µ,C). Additionally, we assume that the underlying
true probability function is p0(t) = H(a0(t)), and a0(t), the true GP, has a continuously
differentiable sample path on T . Without loss of generality, we assume a linear mean function
µ(t) = β0 + β1t. The proof for the case of m-polynomial is easily extended. In addition, we
assume that the true covariance function has the form C0(tu, tv; Θ) = C0(|tu − tv|), where
C0 is a positive multiple of a nowhere-zero density function of one real variable. In our
model, we consider a simple form of covariance function (6) without the jitter part. Then
C0(t) = θ
2
1exp
{
−r2sin2( pi
θ2
t)
}
. We rewrite C0(t) ≡ C0(t; θ1, r, θ2) to prepare for the coming
discussion.
Posterior consistency using GP priors has been extensively studied, see Choudhuri et al.
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(2004), Choi and Schervish (2004, 2007), Ghosal and Roy (2006), and Tokdar and Ghosh
(2007), among others. However, little is known about the type of LGP models proposed
in this paper. We first present posterior consistency results based on a general modeling
framework under a wide class of GP priors a(·) and link functions H, which can be any
strictly increasing, Lipschitz continuous function. Our proposed LGP model in (9) is simply
a special case of the general results. The proofs of all lemmas and theorems stated in this
section are given in Appendix B.
To start, let F be the set of Borel measurable functions defined on R, the real line. For
now, assume that we have a topology on F that measures the distance between any two
functions in F . We also follow Ghosal et al. (1999), to define a probability measure on the
functional space. That is, we operate under the probability space (F , σF , PF), where σF is
the σ-field of F and PF is the probability measure for functions. Suppose p(t) ∈ F , and let Pp
stand for the probability measure corresponding to p(t) on the probability space for the real
line, (R,B, P ), where B and P are the Borel set and the probability measure on the real line,
respectively. To clarify, we use (F , σF , PF) and (R,B, P ) to denote the probability spaces
for random functions and random variables, respectively. Denote K =
∑n
j=1Kj. Dropping
index j we let (et1 , . . . , etK ) be the collection of K observed binary outcomes across n patients,
sorted over time. Under (9) each etk | p(tk) ∼ Bern(p(tk)). We assign prior distribution Π
for p(t) and the posterior distribution given et1 , . . . , etK , denoted by Π(· | et1 , . . . , etK ). We
will show consistency of the posterior distribution of p under some regularity conditions, if
etk ’s are generated conditional on the true function p0(t), i.e., etk | p0(tk) ∼ Bern(p0(tk)).
Below we introduce the metric on F , three lemmas, and the main theorem.
Definition 1. Let F be the set of Borel measurable functions defined on R. For any f0 ∈ F ,
denote the Kullback-Leibler neighborhood KL(f0) = {f :
∫
f0log(f0/f) < }. Let Π be a
prior on F , we say f0 is in the K-L support of Π if Π(KL(f0)) > 0 for all  > 0.
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Lemma 1. Let ([0, TE],B, P ) be a probability space on the real line, and let F be the set
of all real-valued Borel measurable functions f : [0, TE] → [0, 1]. Let P (t) = l(t)/TE be a
probability measure, where l(t) is the Lebesgue measure on [0, TE]. Define
d(f, g) = inf{ : P ({t : |f(t)− g(t)| > }) < }.
Then d(·, ·) induces a metric, and fK converges to f in probability if and only if limK→∞d(fK , f) =
0.
Lemma 2. Let 0 < 0 <
1
2
and 0 < a, b < 1− 0. Then there exists a constant L depending
on 0 such that
a log
a
b
+ (1− a) log 1− a
1− b ≤ L(a− b)
2.
Lemma 3. Assume the compact supports of θ1, r, θ2 are B1, B2 and B3 respectively. Let
B = B1 × B2 × B3, a compact support of (θ1, r, θ2). Define two functions ρ1(θ1, r, θ2) =
C0(0; θ1, r, θ2) and ρ2(θ1, r, θ2) = −C ′′0 (0; θ1, r, θ2), where C ′′0 is the second derivative of C0.
Let a(·) be the GP on T in (9), where T is a bounded subset of R. Then a(·) has differentiable
sample paths and the derivative process a′(·) is also a GP. Further, there exist constants A
and d1, d2 such that
sup(θ1,r,θ2)∈BPr
{
supt∈[0,TE ]|a(t)| > Mn | θ1, r, θ2
} ≤ Ae−d1n
sup(θ1,r,θ2)∈BPr
{
supt∈[0,TE ]|a′(t)| > Mn | θ1, r, θ2
} ≤ Ae−d2n,
where Mn = O(n
1/2).
Next we present the main results in Theorem 1. Choi and Schervish (2007) proposed a
Consistency Theorem (see the Appendix C) as an extension of Schwartz’s theorem (Schwartz,
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1965) to independent but non-identically distributed cases. We make use of such an extension
to achieve the posterior consistency for our proposed LGP by verifying the two conditions
in Choi and Schervish (2007).
Theorem 1. Suppose that K/n = O(1), i.e., when the number of patients n goes to infinity,
the total number of distinct observational time points K =
∑n
j=1Kj in [0, TE] also goes to
infinity. Assume that the mean function µ(·) and C(·, ·) in the Gaussian process prior (9)
satisfy the following conditions:
1. C(·, ·) is nonsingular,
2. C(tu, tv) has the form C0(|tu− tv|), where C0(t) is a positive multiple of a nowhere zero
density function on R and four times continuously differentiable on R,
3. the mean function µ(t) is continuously differentiable in [0, TE], and
4. there exist 0 < δ < 1
2
and b1, b2 > 0 such that
Pr(θ21 > n
δ) < b1exp(−b2n), P r(r2 > nδ) < b1exp(−b2n),
P r(θ22 < n
−δ) < b1exp(−b2n).
Let PK0 denote the joint distribution of {etk}Kk=1 assuming that p0(t) = H(a0(t)) is the true
probability function, where a0(t) is the true GP that has a continuously differentiable sample
path on T . Then for every  > 0, letting S1 (p0) = {p ∈ F : d(p, p0) > }, as n→∞
Π{S1 (p0) | et1 , . . . , etK} → 0 [P∞0 ] (10)
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In addition, for every  > 0, letting S2 (p0) = {p ∈ F :
∫ |p(t)− p0(t)|dt > }, as n→∞
Π{S2 | et1 , . . . , etK} → 0 [P∞0 ] (11)
In general, if more hyperparameters are introduced in the covariance function, we can
verify posterior consistency by assuming compact supports of hyperparmaters and proper
continuity conditions as in Theorem 1.
4 Posterior Inference
4.1 Forecast
An important and useful feature of the LGP model is the ability to forecast, i.e., making
predictions on eij(tKij+s) for future time points tKij+s, s = 1, 2, . . . , Sij. The forecast uses
the posterior predictive distribution p{eij(tKij+s) | eK}, where eK are observed data at Kij
past time points. In particular, define the posterior predictive probability of response as
qijs ≡ Pr
{
eij(tKij+s) = 1 | eK
}
= Pr
{
aij(tKij+s) > ah | eK
}
=
∫
I
{
aij(tKij+s) > ah
}
p
{
aij(tKij+s) | aKij ,mi,βi,Θ
}
× p (aKij ,mi,βi,Θ | eK) daij(tKij+s) daKij dmi dβi dΘ. (12)
The key component in qijs is the conditional distribution p
{
aij(tKij+s) | aKij ,mi,βi,Θ
}
, for
all future points tKij+s, s = 1, 2, . . . , Sij. Therefore, we consider the vector a
(S−K)
ij =(
aij(tKij+1), aij(tKij+2), . . . , aij(tKij+Sij)
)′
, the latent Gaussian variables for future time points.
By definition of the GP model, the joint distribution of p
{
aKij ,a
(S−K)
ij | mi,βi,Θ
}
is a mul-
tivariate Gaussian, and so is the conditional p
{
aij(tKij+s) | aKij ,mi,βi,Θ
}
. Denote its con-
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ditional CDF by ΦS−K|K
(· | aKij ,mi,βi,Θ). Then the Monte Carlo estimate of qijs is given
by
qˆijs =
B∑
b=1
1− ΦS−K|K
(
ah | aK,(b)ij ,m(b)i ,β(b)i ,Θ(b)
)
B
, (13)
where superscript (b) denotes the MCMC sample of the b-th iteration and B is the total
number of MCMC samples kept for posterior inference.
Note that the forecast is subject-j-specific. That is, based on the observed outcomes for
patient j, the forecast could be different due to the subject-specific τij in our original LGP
model (1). This is useful in practice allowing individual patients and their physicians to
prepare for future disease relapses.
4.2 Trial Monitoring Rules
In Section 2.1, we assume that the treatment mean effect for arm i is µi(t) = βi0 + βi1t +
· · ·+ βi,mitmi with a random degree mi. For example, when mi = 1 and slope βi1 is positive,
the mean effect µi(t) is a simple linear function increasing with time; if mi = 2 with βi2 < 0,
the mean effect µi(t) first increases and then decreases, potentially due to drug resistance.
Estimating βi for two arms allows for the comparison of the overall drug effects and hence
trial monitoring. For example, if the experimental arm is considered to perform no better
than the control arm in terms of increasing disease remission time, the trial should be stopped
early due to ethical and logistic reasons.
Denote the duration of the disease remission (DDR) as
Ti(βi,mi) = l{t : µi(t) > ah}, (14)
where l{} is the Lebesgue measure on the real line. That is, Ti is the length of time intervals
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in which µi(t) is above ah for arm i, i.e., patients stay in remission. The arm with longer
DDR is more desirable.
The proposed monitoring criterion uses the posterior probability
η = Pr(T2 > T1 + δ | eK)
=
∫
I {T2(β2,m2) > T1(β1,m1) + δ} p(β,m | eK) dβ dm, (15)
where δ ≥ 0 is a threshold that defines the desirable increment of the efficacy outcome for
the experimental arm over the control. The value of δ is fixed by investigators, and should
reflect the minimum clinically meaningful improvement. A larger η value indicates a larger
chance that treatment 2 is better at keeping patients in remission than treatment 1.
The Monte Carlo estimate of η is given by
ηˆ =
B∑
b=1
I
{
T2(β
(b)
2 ,m
(b)
2 ) > T1(β
(b)
1 ,m
(b)
1 ) + δ
}
B
, (16)
Let ξU be an upper probability boundary above which the trial will be terminated early
and the experimental treatment declared superior if Pr(T2 > T1 + δ | eK) ≥ ξU . Similarly,
let ξL be a lower boundary below which the trial will be terminated early due to futility if
Pr(T2 > T1 + δ | eK) ≤ ξL.
Our proposed trial-monitoring rules are given as
Decision =

stop and declare arm 2 superior if ηˆ ≥ ξU ,
continue enrolling patients if ξL < ηˆ < ξU ,
stop and declare arm 2 not superior if ηˆ ≤ ξL.
Cutoffs ξU and ξL can be calibrated based on simulations. The values ξU = 0.95 and ξL = 0.05
provided desirable performance in the simulation for the lupus trial.
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5 Model Assessment via Sensitivity Analysis
When making forecasts on eij(tKij+s) for future time points, three factors can affect the
forecasting accuracy: 1) the choice of the mean functions µi(t) and covariance functions
τij(t), 2) the number of observed time points Kij at the time of forecast, and 3) the choice
of the threshold ah. To evaluate the impact of these model components, we perform a
sensitivity analysis based on simulation. To simplify the simulation setup, we only consider
data from one arm and focus on the accuracy of posterior estimation and forecast instead of
trial characteristics. Therefore the index i is dropped in the discussion within this section.
We assumed that the sample size was 100 patients for a single arm. We first generated
values aK given µ(t) and τj(t) at a total of 35 time points t1, t2, . . . , t35, out of which the first
Kj ≤ 32 time points were used to predict the responses of patient j at the last three time
points. After generating aK , we generated eK given the threshold ah of our choice. Without
loss of generality, we assumed that all the patients had the same Kj = K for j = 1. . . . , 100.
We specified various choices of K = 20, 23, 26, 29, 32 to study their effects on forecasting in
each scenario. To show the robustness to the threshold ah, we assumed ah = 0 when we
generated the simulation data and set ah = 0 or ah = 0.5 when we fitted models to the
simulated data.
We considered five scenarios. In scenarios 1-3, we generated data by using different
polynomial mean functions µ(t) and the covariance function (6) with θ1 = 1, θ2 = 3.5 and
r = 2. For ease of exposition, we display (6) again: Cuv(Θ) = θ
2
1 exp
{
−r2 sin2(pi(tu−tv)
θ2
)
}
+
δuvJ
2. In scenario 1, the true mean µ(t) = β0, where β0 = −0.8. In scenario 2, the true
µ(t) = β0 + β1t, where β0 = −0.8, β1 = 0.4. In scenario 3, the true µ(t) = β0 + β1t + β2t2,
where β0 = −1, β1 = 3.5, β2 = −1. In words, scenarios 1-3 represent constant mean, linear
mean, and quadratic mean respectively. We fitted the LGP model (8) to the simulated data
and assumed vague priors β ∼ Gaussian(0, 102I), θ1, θ2, r ∼ Gaussian(0, 102).
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In scenario 4, we generated data from the trigonometric mean function µ(t) = α +
sin(β0pit) with α = −0.8, β0 = 1.5, and the covariance function (5) with θ1 = 1 and r = 3.
We then fitted the model using the same trigonometric mean function but with unknown pa-
rameters, and the covariance function (5) to the simulated data and estimated unknown pa-
rameters α, β0, θ1 and r, for which we also assumed vague priors α, β0, θ1, r ∼ Normal(0, 102).
In scenarios 1-4, we took periodicity into consideration by placing the trigonometric
function in the fitted model. Scenarios 1-3 had a trigonometric function in the covariance
function, while scenario 4 assumed a trigonometric mean function. To show the differences
between these two configurations, in Figure 2 we plotted simulated a for 20 randomly selected
replications under scenarios 1-4. We can see that the overall mean in the top right panel
increases with time and each patient curve has a different periodic behavior in scenario 2. In
contrast, in the bottom right panel for scenario 4, the overall mean has an obvious periodic
pattern and each individual curve has its own variability around the mean.
As discussed above, putting a trigonometric function in the mean function µ(t) or covari-
ance function τj(t) leads to different group and individual behaviors. Since both models are
periodic, we designed scenario 5 to investigate whether one model can predict for the other.
For this purpose, we generated data from the true model with mean µ(t) = sin(β0pit), where
β0 = 1 and τj(t) from a GP with zero mean and covariance function C in (5) with θ1 = 1
and r = 3, which does not have a trigonometric component. Then we fitted model (8) with
a polynomial mean function and the covariance function having trigonometric components.
For each of the five scenarios described above, we specified five different values for K =
20, 23, 26, 29, 32, and two threshold values ah = 0 or 0.5. Therefore, we obtained a total of
5× 2× 5 = 50 cases. For each case, we implemented the proposed LGP model with 10,000
MCMC iterations with a burn-in of 2,000 iterations, finished in 30 minutes. The convergence
of the MCMC algorithm was diagnosed by standard methods in R package coda. All the
chains converged quickly and mixed well.
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Figure 2: Sample curves of latent variable values for 20 randomly selected patients in sce-
narios 1-4. The red curve in each plot represents the mean function µ(t) of the GP. The
horizontal blue line represents the threshold ah.
Figure 3 shows the proportion of posterior estimates of the degree of polynomial m
in scenarios 1-3. Recall that m follows a discrete uniform prior taking values in the set
{0, 1, 2, . . . ,M}; here we set M = 5. We can see that the degree of the polynomial from the
true model dominates the posterior estimates. In scenarios 4-5 there are no true m values
since the true µ(t) is not a polynomial function.
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Figure 3: The proportion of posterior estimates of m in all cases for scenarios 1-3 in the
simulation.
For each case, we computed the average posterior predictive probability of response at a
future time point ts over 100 patients, defined as
qs =
1
100
∑100
j=1 Pr{ej(ts) = 1 | eK}, where Pr{ej(ts) = 1 | eK} was calculated according
to (12) and (13). We used ts = 33, 34 and 35, since the lupus trial protocol plans to make
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forecasts at these three future time points. Also, we computed the posterior mean DDR
Tˆ =
1
B
B∑
b=1
l{t : µ(t;β(b),m(b)) > ah}.
Table 1 summarizes the results.
After obtaining the posterior imputation of the latent variables aK and posterior pre-
dictive values of a(35−K) for the new time points, we plotted 20 realizations of the latent
variables for one randomly selected patient in case (K = 32, ah = 0) for scenario 2 and case
(K = 29, ah = 0) for scenario 4 as shown in Figures 4 and 5, respectively. The left panel
presents the latent variable values given the first 32 observed time points and the right panel
presents those with the first 29 time points observed. It can be seen that our model fits the
simulated data well in both panels.
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Figure 4: A set of 20 realizations of latent variables for two cases in scenario 2. The left panel
presents the latent variable values for one patient with the first 32 time points observed. The
right panel presents one patient with the first 29 time points observed. The red solid line
represents the truth. Black solid lines represent 20 realizations at observed time points, and
blue dashed lines represent predicted values at future time points.
In scenario 5, we generated simulated data using the model with a trigonometric mean
function and covariance function (5) without trigonometricity, but fitted the model with the
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Table 1: True probability, empirical probability and average posterior predictive estimate
(PPE) of response probability at future time point t33, t34 and t35. The posterior mean DDR,
Tˆ , is also presented.
q33 q34 q35 Tˆ
Scenario 1 Truth 0.2130 0.2130 0.2130 0
Empirical 0.28 0.22 0.25 8.87
K = 32, ah = 0 PPE 0.2212 0.2398 0.2491 0
K = 32, ah = 0.5 PPE 0.2205 0.2389 0.2488 0
K = 29, ah = 0 PPE 0.2683 0.2637 0.2613 0
K = 29, ah = 0.5 PPE 0.2712 0.2667 0.2640 0
K = 26, ah = 0 PPE 0.2734 0.2691 0.2663 0
K = 26, ah = 0.5 PPE 0.2726 0.2687 0.2665 0
K = 23, ah = 0 PPE 0.2445 0.2443 0.2442 0
K = 23, ah = 0.5 PPE 0.2450 0.2447 0.2446 0
K = 20, ah = 0 PPE 0.2377 0.2376 0.2376 0
K = 20, ah = 0.5 PPE 0.2399 0.2399 0.2399 0
Scenario 2 Truth 0.6976 0.7113 0.7248 15
Empirical 0.74 0.75 0.76 18.06
K = 32, ah = 0 PPE 0.7459 0.7568 0.7717 18.807
K = 32, ah = 0.5 PPE 0.7482 0.7604 0.7755 18.701
K = 29, ah = 0 PPE 0.7778 0.7920 0.8053 19.008
K = 29, ah = 0.5 PPE 0.7800 0.7944 0.8075 19.142
K = 26, ah = 0 PPE 0.7684 0.7826 0.7960 18.762
K = 26, ah = 0.5 PPE 0.7747 0.7878 0.8010 18.896
K = 23, ah = 0 PPE 0.7906 0.8034 0.8156 18.892
K = 23, ah = 0.5 PPE 0.7979 0.8106 0.8227 19.353
K = 20, ah = 0 PPE 0.7732 0.7852 0.7967 17.985
K = 20, ah = 0.5 PPE 0.7718 0.7840 0.7957 18.269
Scenario 3 Truth 0.3676 0.2557 0.1599 28.723
Empirical 0.42 0.30 0.19 27.55
K = 32, ah = 0 PPE 0.4179 0.3140 0.2244 29.457
K = 32, ah = 0.5 PPEn 0.4212 0.3201 0.2317 29.506
K = 29, ah = 0 PPE 0.4763 0.3723 0.2731 29.893
K = 29, ah = 0.5 PPE 0.4594 0.3538 0.2546 29.728
K = 26, ah = 0 PPE 0.6648 0.5795 0.4873 31.261
K = 26, ah = 0.5 PPE 0.6465 0.5625 0.4742 30.962
K = 23, ah = 0 PPE 0.4690 0.3814 0.2999 29.547
K = 23, ah = 0.5 PPE 0.3744 0.2866 0.2105 28.762
K = 20, ah = 0 PPE 0.7575 0.7160 0.6731 30.931
K = 20, ah = 0.5 PPE 0.7483 0.7068 0.6646 30.869
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q33 q34 q35 Tˆ
Scenario 4 Truth 0.2610 0.1349 0.0669 8.194
Empirical 0.31 0.18 0.12 10.980
K = 32, ah = 0 PPE 0.3118 0.1660 0.0823 9.985
K = 32, ah = 0.5 PPE 0.3123 0.1664 0.0825 9.988
K = 29, ah = 0 PPE 0.2458 0.1228 0.0614 9.687
K = 29, ah = 0.5 PPE 0.2458 0.1228 0.0614 9.687
K = 26, ah = 0 PPE 0.2640 0.1366 0.0683 9.095
K = 26, ah = 0.5 PPE 0.2687 0.1400 0.0699 9.093
K = 23, ah = 0 PPE 0.2528 0.1314 0.0677 9.143
K = 23, ah = 0.5 PPE 0.2522 0.1310 0.0675 9.143
K = 20, ah = 0 PPE 0.2641 0.1387 0.0710 9.230
K = 20, ah = 0.5 PPE 0.2632 0.1378 0.0705 9.231
Scenario 5 Truth 0.2104 0.1720 0.1599 20.00
Empirical 0.23 0.22 0.19 19.54
K = 32, ah = 0 PPE 0.1544 0.0679 0.0181 23.62
K = 32, ah = 0.5 PPE 0.1447 0.0711 0.0287 23.06
K = 29, ah = 0 PPE 0.0068 0.0002 0.0000 19.52
K = 29, ah = 0.5 PPE 0.0103 0.0003 0.0000 19.66
K = 26, ah = 0 PPE 0 0 0 17.70
K = 26, ah = 0.5 PPE 0 0 0 17.59
K = 23, ah = 0 PPE 0.0035 0.0028 0.0024 16.66
K = 23, ah = 0.5 PPE 0.0017 0.0012 0.0011 16.87
K = 20, ah = 0 PPE 1 1 1 25.79
K = 20, ah = 0.5 PPE 0.9960 0.9950 0.9950 25.73
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Figure 5: A set of 20 realizations of latent variables for two cases in scenario 4. The left panel
presents the latent variable values for one patient with the first 32 time points observed. The
right panel presents one patient with the first 29 time points observed. The red solid line
represents the truth. Black solid lines represent 20 realizations at observed time points, and
blue dashed lines represent predicted values at future time points.
polynomial mean function and the trigonometric covariance function (6) to the simulated
data. As seen in Table 1, the predictions are poor. This implies that the model choice is
important in terms of the placement of the trigonometric functions, in the mean or covariance
of the GP.
Next we checked the robustness of the choice of ah. As shown in Table 1, the estimations
remained consistently well when we varied the values of ah (ah = 0 and ah = 0.5). Thus, the
model is robust to choice of ah.
Finally we examined the impact of different K’s on the forecast. From Table 1 and Figure
3, we can see that the fewer the observed time points, i.e. the smaller the value of K, the
worse the prediction. For example, in scenario 3, when K = 32 and ah = 0, the degree
of polynomial of the true model is successfully recovered 99% of times; but when K = 20
and ah = 0, this percentage drops to 85%. Also, the true q33 = 0.3676, while the posterior
estimate of q33 is 0.4179 when (K = 32, ah = 0) and 0.7575 when (K = 20, ah = 0). This
28
also echoes the consistency results in Section 3 to be shown next; that is, the larger the
number of time points observed, the better the estimation.
Next in the lupus trial example, one concern is how to choose the proper time point
to start the forecast, which also depends on the drug effects. Based on previous clinical
experiments and prior knowledge, we can make assumptions about the mean of the the drug
effects and the start time point can be determined by simulation and calibration. Examining
the simulation results observed so far, we decided to use K = 23 as the starting time for
forecast.
6 Trial Example
Using the lupus trial as an example, we simulated a large number of clinical trials on computer
and applied the proposed monitoring rules to examine the operating characteristics of our
method. According to the original trial setup, we set the duration of the simulated trials at
35 weeks and the maximum number of patients to be 200, equally randomized between the
standard arm and experimental arm. We assumed that patients were recruited over time
and the number of patients enrolled weekly for each arm was a random number following
a discrete uniform in {2, 3, 4}. Patients were observed and followed each week, when their
responses e’s were recorded. The experimental treatment (arm 2) is considered more effective
than the control (arm 1) if the DDR in (14) for the treatment arm T2 is at least 2 weeks
longer than that of the control arm T1, i.e., the minimum difference between the two arms
must be δ = 2.
We considered six scenarios and simulated 100 trials for each scenario. The binary re-
sponse outcomes were generated over time using the following scheme. We first specified
true mean functions (see Table 2 for different µi(t)) and the true covariance function (6)
with θ1 = 1, θ2 = 3.5 and r = 2. We then generated the LGP a(tk) and e(tk) at 35 weeks of
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Table 2: True Values of mi, βi and Ti, i = 1, 2 for all six scenarios in the simulation.
Group mi βi Ti
Scenario 1 Standard 2 (-2, 3.5, -1) 20.6
Experimental 3 (-1.4, 7.5, -5.3, 1) 27.6
Scenario 2 Standard 3 (-1.5, 7.5, -5.3, 1) 25.9
Experimental 2 (-1, 3.5, -1) 28.7
Scenario 3 Standard 3 (-2.4, 7.5, -5.3, 1) 15.4
Experimental 2 (-2.4, 3.5, -1) 16.3
Scenario 4 Standard 3 (-2, 7.5, -5.3, 1) 19.7
Experimental 2 (-1, 3.5, -1) 28.7
Scenario 5 Standard 3 (-1.28, 3.5, -1) 26.7
Experimental 3 (-1.2, 3.6, -1) 28.6
Scenario 6 Standard 2 (-0.39, 0.3) 22.0
Experimental 2 (-1.1, 1) 24.0
follow up, k = 1, 2, . . . , 35.
For all six scenarios, the true DDR Ti according to the true µi(t) were calculated, and
the configurations including mi, βi and Ti, i = 1, 2 are displayed in Table 2. Figure 6 shows
the true mean functions of the standard and experimental arms in all six scenarios, in which
we also mark the true Ti values. The arm with a larger Ti value is more effective since it
leads to a longer DDR. For example, in scenario 1, T1 = 20.616 and T2 = 27.616, so arm 2,
the experimental treatment, is better.
We fitted the proposed model (8) to the simulated data and assumed vague priors β ∼
Normal(0, 102I), θ1, θ2, r ∼ Normal(0, 102). The trial monitoring started at week K = 23 and
was based on the proposed monitoring rules with δ = 2. Table 3 summarizes the operating
characteristics of the LGP method for all six scenarios, including the average duration of
trials, the maximum duration of trials, the average number of patients studied and stopping
probabilities.
In scenario 1, m1 = 2 and m2 = 3, and from Figure 6, patients in the experimental arm
relapse more often than patients in the control arm. However, the experimental arm is still
preferred since it has longer DDR as T2 = 27.616 > (20.616 + 2) = (T1 + δ). Thus, scenario
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Figure 6: The true DDR Ti and the true mean functions µi(t) in the control and experimental
arms in all six scenarios for the lupus trial simulation. The red line represents the true mean
in the control arm, while the blue line represents the true mean in the experimental arm.
The black horizontal line represents the threshold ah = 0.
1 explored the ability of the proposed LGP method to stop if the experimental arm has
a longer DDR but more frequent relapses. The average trial duration was 24.9 weeks and
the maximum trial duration was 29 weeks, which indicated that the trial stopped quickly
after it was monitored at week 23. The average number of patients was 76.1 per group and
the maximum was 100 patients. Among 100 simulated trials, 97 were stopped early due to
superiority.
In scenario 2, m1 = 3,m2 = 2 and T1 = 25.939, T2 = 28.723. Here T2−T1 ≈ 2.8 which is
close to δ = 2. Among the 100 trials simulated, 52 stopped early due to superiority. In this
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Table 3: Results for the simulations based on the lupus trial. AD: average trial duration
(weeks); MD: maximum duration (weeks); AP: average number of patients in each group.
Group Ti AD MD AP Stopping probabilities
Scenario 1 Standard 20.6 24.9 29 76.1 97%(superiority)
Experimental 27.6
Scenario 2 Standard 25.9 29.72 35 87.43 52%(superiority)
Experimental 28.7
Scenario 3 Standard 15.4 29.06 35 87.68 60%(futility)
Experimental 16.3
Scenario 4 Standard 19.7 23.31 26 70.65 100%(superiority)
Experimental 28.7
Scenario 5 Standard 26.7 29.11 35 86.91 25%(superiority) and 30%(futility)
Experimental 28.6
Scenario 6 Standard 22.0 30.90 35 91.59 16%(superiority) and 19%(futility)
Experimental 24.0
scenario, the average trial duration was 29.72 weeks and the maximum trial duration was 35
weeks. The average number of patients was 87.43 per group.
In scenario 3, m1 = 3,m2 = 2 and T1 = 15.414, T2 = 16.279. Among the 100 simulated
trials, 60 stopped early due to futility as expected. In this scenario, the average trial duration
was 29.06 weeks. The average number of patients was 87.68 per group. In scenario 4,
m1 = 3,m2 = 2 and T1 = 19.736, T2 = 28.723, implying that arm 2 was much better than
arm 1. All 100 trials stopped early due to superiority of arm 2. The average trial duration
was 23.31 weeks and the maximum trial duration was 26 weeks. The average number of
patients was 70.65 per group.
In the last two scenarios, different arms had the same mi value. In scenario 5, m1 = m2 =
2. The average trial duration was 29.11 weeks, and the average number of patients was 86.91
per group. Among the 100 trials simulated, 25 stopped due to superiority, 30 stopped due
to futility, and 45 did not stop early. In scenario 6, m1 = m2 = 1 and T1 = 22, T2 = 24. The
DDR in arm 2 was exactly 2 weeks longer than in arm 1, making it difficult to stop early.
Among 100 simulated trials, 65 didn’t stop early, 16 stopped early due to superiority, and 19
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stopped early due to futility. The average trial duration was 30.9 weeks and the maximum
trial duration was 35 weeks. The average number of patients was 91.59 per group.
In summary, the proposed LGP model and trial monitoring rules exhibited desirable
operating characteristics in all six scenarios.
7 Discussion
We have proposed a Bayesian LGP model for monitoring clinical trials with binary repeated
outcomes. Through the posterior estimates, we can predict the probability of efficacy re-
sponse for each patient at future time points. The proposed trial monitoring rules allow
for early termination of a trial if one arm is considered more effective than the other. The
Bayesian paradigm works very well and yields desirable results in our simulation studies.
Although our current models are set up for binary outcomes, they can be easily extended
to other applications with ordinal or categorical outcomes. Furthermore, the LGP provides a
framework for the inclusion of patient- or group-specific covariates such as patients’ weights,
ages, etc., which can be easily implemented by expanding the columns of the design matrix
Xij in (4). This will be a future direction of our research.
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APPENDIX A: MCMC Details
Joint Distributions
P (eK ,aK ,m,β,Θ) = P (eK | aK)P (aK | β,m,Θ)P (β |m)P (m)P (Θ)
=
[
2∏
i=1
[ Ni∏
j=1
{ Kij∏
k=1
{
P (eijk | aijk) = I(aijk > ah)I(eijk = 1)
+I(aijk <= ah)I(eijk = 0)
}}
×(2pi)−
Kij
2 |C(tij)|− 12
× exp
{
− 1
2
(aKij −Xijβi)′C(tij)−1(aKij −Xijβi)
}]
×(2pi)−mi+12 |σ20Imi+1|−
1
2
× exp
{
− 1
2
(βi − µmi+10 )′(σ20Imi+1)−1(βi − µmi+10 )
}]
×P (m)P (Θ)
where aKij = (aij1, . . . , aijKij)
′,βi = (βi0, βi1, . . . , βi,mi)
′, Imi+1 is an (mi + 1) × (mi + 1)
dimension identity matrix, and
Xij =

1 t1 · · · tmi1
1 t2 · · · tmi2
...
...
. . .
...
1 tKij · · · tmiKij

.
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Full Conditional
Algorithm for simulating aKij
P (aKij | eK ,β,m,Θ) ∝
{ Kij∏
k=1
P (eijk | aijk) = I(aijk > ah)I(eijk = 1)
+I(aijk <= ah)I(eijk = 0)
}
×(2pi)−
Kij
2 |C(tij)|− 12
× exp
{
− 1
2
(aKij −Xijβi)′C(tij)−1(aKij −Xijβi)
}
To sample this truncated multivariate normal distribution, we use the method of Geweke
(1991) to compose a cycle of Gibbs steps through the components of aij.
To draw the samples from multivariate normal distribution subject to linear inequality
restrictions:
x ∼ N(µ,Σ). a < Dx < b,
where x is n−dimensional vector, a and b are m−dimensional vectors, and D is m×n matrix
imposing linear inequality restrictions.
This is equivalent to:
z ∼ N(0, T ), α < z < β. (17)
where
T = DΣD′, α = a−Dµ, β = b−Dµ,
and we then take x = µ+D−1z.
Suppose that in the non-truncated distribution N(0, T ),
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E[zi | z1, . . . , zi−1, zi+1, . . . , zn] =
∑
j 6=i
cijzj.
Then in the truncated normal distribution of (17), the distribution of zi conditional on
{z1, . . . , zi−1, zi+1, . . . , zn} has the construction
zi =
∑
j 6=i
cijzj + hii, i ∼ TN [(αi −
∑
j 6=i
cijzj)/hi, (βi −
∑
j 6=i
cijzj)/hi].
Denote the vectors of coefficients ci = (ci1, . . . , ci,i−1, ci,i+1, . . . , cin)′, i = 1, . . . , n. From
the conventional theory of the conditional multivariate normal distribution, ci = −(T ii)−1T i,<i
and h2i = (T
ii)−1, where T ii is the element in row i and column i of T−1, and T i,<i is row i
of T−1 with T ii deleted.
Therefore, to sample aij from the posterior conditional probabilities, we compose a cycle
of Kij Gibbs steps through the components of aij. In the kth step of this cycle, aijk is
simulated from aijk | eK , aijq(q 6= k),βi,mi,Θ}, which is a univariate normal distribution
truncated to one region.
Sample the degree of polynomial mi
P (mi | aK ,Θ) ∝ P (aK |m,Θ)P (mi) = P (mi)
∫
P (aK | β,m,Θ)P (β |m) dβ
∝ P (mi) |Ami |
1
2
|σ20Imi+1|
1
2
× exp
{1
2
b′miA
′
mi
bmi −
1
2
µmi+1
′
0 (σ
2
0Imi+1)
−1µmi+10
}
,
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where
Ami =

Nj∑
j=1
X ′ijC(tij)
−1Xij + (σ20Imi+1)
−1

−1
,
bmi =

Nj∑
j=1
X ′ijC(tij)
−1aKij + (σ
2
0Imi+1)
−1µmi+10
 .
We only consider (M + 1) possible models, so we compute rh = P (h | aK ,Θ), h =
0, 1, . . . ,M . Let wj = rj/
∑M
h=0 rh, then we sample mi ∼ Multinomial(w0, . . . , wM).
Posterior conditional distribution of βi
The posterior conditional distribution of βi is a multivariate normal distribution.
P (βi | aK ,m,Θ) ∼MVN(µβi ,

Nj∑
j=1
X ′ijC(tij)
−1Xij + (σ20Imi+1)
−1

−1
),
where
µβi =

Nj∑
j=1
X ′ijC(tij)
−1Xij + (σ20Imi+1)
−1

−1
×

Nj∑
j=1
X ′ijC(tij)
−1aKij + (σ
2
0Imi+1)
−1µmi+10
 .
Hybrid Monte Carlo algorithm to sample Θ
We apply Hybrid Monte Carlo method to sample Θ. Suppose we want to sample from
the canonical distribution for a set of variables, Θ = {θ1, θ2, . . . , θn}, with respect to the
potential energy function E(Θ). Assuming that E(Θ) is differentiable with respect to θi,
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this canonical distribution is
P (Θ) =
1
ZE
exp{−E(Θ)}.
We then introduce another set of variables, w = {w1, w2, . . . , wn}, one wi for each θi, with
a kinetic energy function, P (w) = 1
ZK
exp{−K(w)} = (2pi)−n/2 exp(−1
2
∑
iw
2
i ). The total
energy function, known as Hamiltonian, is H(Θ,w) = E(Θ)+K(w) = E(Θ)+ 1
2
∑
iw
2
i . The
canonical distribution defined by this energy function is P (Θ,w) = 1
ZH
exp{−H(Θ,w)} =
P (Θ)P (w).
The unknown parameters (θ1, θ2, . . . , θn) can be sampled from the marginal distribution
for Θ by ignoring the values we obtained forw. In practice, the differentiation equations that
describe the Hamiltonian equilibrium through time need to be discretized. In our case, to
obtain the posterior samples of our unknown parameters, we use leapfrog discretization. In
order to perform a leapfrog discretization, the derivative of the log of the posterior probability
with respect to hyper-parameters is needed.
A single leapfrog iteration calculates approximations θˆ and wˆ at time τ +  from θˆ and
wˆ at time τ as follows:
wˆi(τ +

2
) = wˆi(τ)− 
2
∂E
∂θi
{θˆi(τ)}
θˆi(τ + ) = θˆi(τ) + wˆi(τ +

2
)
wˆi(τ + ) = wˆi(τ +

2
)− 
2
∂E
∂θi
{θˆi(τ + )}.
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The hybrid Monte Carlo algorithm
Given values for the magnitude of the leapfrog stepsize, 0, and the number of leapfrog
steps, L, the dynamical transitions of the hybrid Monte Carlo algorithm operate as follows:
• Randomly choose a direction, λ, for the trajectory with the two values λ = +1
representing a forward trajectory, and λ = −1 representing a backward trajectory,
both being equally likely.
• Starting from the current state, (θ, w) = (θˆ(0), wˆ(0)), perform L leapfrog steps with
a stepsize of  = λ0, resulting in the state (θˆ(L), wˆ(L)) = (θ
∗, w∗).
• Regard (θ∗, w∗) as a candidate for the next state, as in the Metropolis algorithm:
accepting it with probability A{(θ, w), (θ∗, w∗)} = min{1, exp{−(H(θ∗, w∗) −
H(θ, w))}}, otherwise letting the new state be the same as the old one.
For our problem,
E(Θ) =
1
2
2∑
i=1
Ni∑
j=1
{
(aKij −Xijβi)′C(tij)−1(aKij −Xijβi) + log(|C(tij)|)
}
−logP (Θ),
∂E(Θ)
∂Θ
= −1
2
2∑
i=1
Ni∑
j=1
(aKij −Xijβi)′C(tij)−1
∂C(tij)
∂Θ
C(tij)
−1(aKij −Xijβi)
+
1
2
2∑
i=1
Ni∑
j=1
tr
{
C(tij)
−1∂C(tij)
∂Θ
)
}
− ∂logP (Θ)
∂Θ
.
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Since Cuv = C(tu, tv) = θ
2
1 exp
{
−r2 sin2(pi(tu−tv)
θ2
)
}
+ δuvJ
2, and we have the formula
∂C−1
∂θ
= −C−1 ∂C
∂θ
C−1, therefore,
C ′θ1(ti, tj) =
∂C
∂θ1
= 2θ1 exp
{
−r2 sin2(pi(tu − tv)
θ2
)
}
,
C ′r(ti, tj) =
∂C
∂r
= θ21 exp
{
−r2 sin2(pi(tu − tv)
θ2
)
}
(−2r) sin2
{
pi(tu − tv)
θ2
}
,
C ′r(ti, tj) =
∂C
∂θ2
= 2r2θ21 exp
{
−r2 sin2(pi(tu − tv)
θ2
)
}
sin
{
pi(tu − tv)
θ2
}
cos
{
pi(tu − tv)
θ2
}{
pi(tu − tv)
θ22
}
.
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Appendix B: Proofs of Lemmas and Main Theorem
B.1: Proof of Lemma 1
Proof. Clearly d(f, g) ≥ 0 and d(f, g) = d(g, f). Also, we can easily show d(f, g) = 0 if and
only if f = g a.s.. To prove d(·, ·) induces a metric, the last condition we need to verify is
triangle inequality d(f, h) ≤ d(f, g) + d(g, h) for each f, g, h ∈ F .
Define Qfg = { : P ({t : |f(t) − g(t)| > }) < }, then d(f, g) = inf Qfg. So we need to
show
inf Qfh ≤ inf Qfg + inf Qgh. (18)
Assuming 1 ∈ Qfg and 2 ∈ Qgh, then
P ({t : |f(t)− h(t)| > 1 + 2}) ≤ P ({t : |f(t)− g(t)| > 1})
+P ({t : |g(t)− h(t)| > 2})
≤ 1 + 2
So if 1 ∈ Qfg and 2 ∈ Qgh, then 1 + 2 ∈ Qfh, which implies (18).
Lastly we show fn converges to f in probability if and only if limn→∞d(fn, f) = 0. First,
assume that limn→∞d(fn, f) = 0. Then for every  > 0 there exists N such that for all
n ≥ N , d(fn, f) ≤ , which is equivalent to P ({t : |fn − f | > }) < . Hence, fn converges
to f in probability. Finally, assume that fn converges to f in probability. Then for every
 > 0, limn→∞P ({t : |fn − f | > }) = 0. So, for every  > 0, there exists N such that for all
n ≥ N , d(fn, f) ≤ , which completes the proof.
B.2: Proof of Lemma 2
Proof. It follows easily from applying Taylor’s expansion to log(a
b
) and log(1−a
1−b ).
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B.3: Proof of Lemma 3
Proof. Our mean function µ(t) = β0 + β1t is continuously differentiable in [0, TE]. For
sufficiently large M ,
Pr(supt|a(t)| > M) ≤ Pr(supt|a(t)− µ(t)| > M − supt|µ(t)|)
≤ Pr(supt|a(t)− µ(t)| > M/2)
Thus, without generality, we assume that the mean function is identically zero.
From the result of Theorem 5 in Ghosal and Roy (2006), there exist constants Aw, cw,
dw(θ1, r, θ2) such that
Pr
{
supt∈[0,TE ]|Dwa(t)| > Mn | θ1, r, θ2
} ≤ Awe−cwdwn,
where w = 0, 1 and cw > 0. Through calculations (details not shown), d
0 = 1/C0(0; θ1, r, θ2) =
1
θ21
, d1 = −1/C ′′0 (0; θ1, r, θ2) = − 12pi2θ21r2/θ22 . Furthermore, since we assume ρ1(θ1, r, θ2) and
ρ2(θ1, r, θ2) are continuous on the compact set B, they are uniformly bounded. Thus, there
exist universal constant S1, S2, S3 and S4 such that
0 < S1 ≤ sup(θ1,r,θ2)∈B|ρ1| ≤ S2
0 < S3 ≤ sup(θ1,r,θ2)∈B|ρ2| ≤ S4
Consequently,
sup(θ1,r,θ2)∈BPr
{
supt∈[0,TE ]|a(t)| > Mn | θ1, r, θ2
} ≤ Ae−d1n
sup(θ1,r,θ2)∈BPr
{
supt∈[0,TE ]|a′(t)| > Mn | θ1, r, θ2
} ≤ Ae−d2n,
where d1 = c0/S2, d1 = c1/S4 and A = max(A0, A1).
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B.4: Proof of Theorem 1
Proof. In trials as the lupus trial, disease relapses frequently. Whenever that happens, an
binary outcome is observed and time recorded. Assuming the relapse time is random, it is
reasonable to assume that K →∞ when n→∞. On the other hand, the theorem will not
be valid if the observational time points are regularly spaced and all patients are observed
at the same time. For example, the theorem will not hold if K1 = · · · = Kn = K0 and we
observe each ejk only at the points TE/k, where k = 1, . . . , K0.
The first condition of the Consistency Theorem in Choi and Schervish (2007) we need to
verify is prior positivity of neighborhoods. If the prior satisfies this condition, the probability
of every Kullback-Leibler (KL) neighborhood of true density function is positive. The density
of etk with respect to the counting measure on {0, 1}, say Q, is given by f(etk) = p(tk)etk (1−
p(tk))
1−etk . For simplicity, the index tk is dropped here. So we have f(e) = pe(1 − p)1−e.
The corresponding true density function is f0(e) = p
e
0(1 − p0)1−e and
∫
f0 log(f0/f) dQ =
p0 log(p0/p) + (1− p0) log((1− p0)/(1− p)).
To show that the probability of every KL neighborhood of true density function is positive,
we first show that Π{f : ∫ f0 log(f0/f) dQ < } > 0 for all  > 0, where Π is the prior for
f , or equivalently, Π{p : p0 log(p0/p) + (1− p0) log((1− p0)/(1− p)) < } > 0 for all  > 0.
Let Υ = {p : ||p − p0||∞ < 121}, where 1 = inf{min(p0, 1 − p0)) : 0 ≤ t ≤ TE} > 0 and
||p− p0||∞ = sup0≤t≤TE(|p(t)− p0(t)|). If p ∈ Υ, following Lemma 2, there exists a constant
L depending only on 1 such that p0 log(p0/p) + (1− p0) log((1− p0)/(1− p)) ≤ L||p− p0||2∞.
Therefore, it suffices to show that Π(p : ||p − p0||∞ < ) > 0 for every  > 0. Since our
link function H is assumed to be bounded and Lipschitz continuous, it suffices to show that
Π(a : ||a− a0||∞ < ) > 0 for every  > 0.
The prior distribution of a is a ∼ GP (µ,C), where ||µ||∞ < A2 and ||µ′||∞ < A3 for
some constants A2 and A3 under our assumptions. Without loss of generality we assume
µ ≡ 0. Choi and Schervish (2004) examined the general result on the uniform support for
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a Gaussian process prior with zero mean. It is easily extended to support [0, TE] and our
mean assumption. Therefore the positivity of neighborhoods holds.
The second condition is the existence of tests. We construct a similar sieve as in Choi
and Schervish (2004) and then construct a test for each element of the sieve.
SIK = {p(·) : p(t) = H(a(t)), ||Dwa||∞ < MK}.
Let p1 be a continuous function on [0, TE]. Let hk = 1 if p1(tk) ≥ p0(tk) and−1 otherwise. Let
r > 0, mK = K
1/2 and IK be the indicators of set U1 = {
∑K
k=1 hk(e0(tk)−p0(tk) > 2mK
√
K},
where e0(tk) ∼ Bernoulli(p0(tk)). For all p1 that satisfy
K∑
k=1
|p1(tk)− p0(tk)| > rK, (19)
by Bernstein’s inequality, we have
EP0(IK) = P0
{
K∑
k=1
hk(e0(tk)− p0(tk) > 2mK
√
K
}
= 2 exp(−1
2
4m2KK
K + 2mK
√
K
) ≤ 2 exp(−2m2K). (20)
Also, let us assume e(tk) ∼ Bernoulli(p(tk)). For all sufficiently large K such that
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mK/
√
K < 4/r and all p satisfying ||p− p1||∞ < r/4, we have
EP (1− IK) = P
{
K∑
k=1
hk(e(tk)− p0(tk) ≤ 2mK
√
K
}
= P
{
1√
K
K∑
k=1
hk(e(tk)− p(tk)) + 1√
K
K∑
k=1
hk(p(tk)− p1(tk))
+
1√
K
K∑
k=1
hk(p1(tk)− p0(tk)) ≤ 2mn
}
≤ P
{
1√
K
K∑
k=1
hk(e(tk)− p(tk)) ≤ r
√
K
4
− r
√
K + 2mK
}
≤ 2 exp(−1
2
r2
1 + r
K), (21)
where the second to last inequality is by Bernstein’s inequality.
We showed how to construct consistent test functions when the inequality (19) holds.
Choi (2007) examined inequality (19) held with metric d introduced in Lemma 1. By (20),
(21) and Lemma 3, the second condition of Consistency Theorem in Choi (2007) is verified.
So far the two conditions of Consistency Theorem in Choi and Schervish (2007) have
been verified. We have showed that the posterior probability
sup(θ1,r,θ2)∈BΠ{S2 | e, θ1, r, θ2} → 0 [P∞0 ], (22)
where S2 =
{
p :
∫ |p(t)− p0(t)|dt > } and e = (et1 , . . . , etK )′.
Finally, let us consider the goal of our theorem. By Fubini’s Theorem,
Π
{
S2 | e
}
=
∫
B
Π{S2 | e, θ1, r, θ2} dΠ {(θ1, r, θ2) | e}
=
∫
B3
∫
B2
∫
B1
Π{S2 | e, θ1, r, θ2} dΠ(θ1 | e) dΠ(r | e) dΠ(θ2 | e).
Since the supermum of the conditional probability in (22) converges to 0 in PK0 probabil-
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ity, the marginal posterior probability converges to 0 in PK0 probability regardless of the
asymptotic distribution of Π(θ1 | e), Π(r | e) and Π(θ2 | e). This is formalized as follows:
Π{S2 | e} =
∫
B3
∫
B2
∫
B1
Π{S2 | e, θ1, r, θ2} dΠ(θ1 | e) dΠ(r | e) dΠ(θ2 | e)
≤ sup(θ1,r,θ2)∈BΠ{S2 | e, θ1, r, θ2}
∫
θ1∈B1
dΠ(θ1 | e)
×
∫
r∈B2
dΠ(r | e)
∫
θ2∈B3
dΠ(θ2 | e) → 0 [P∞0 ]
So, (11) is proved. From Lemma 1, (10) is also proved.
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Appendix C
Theorem (Choi and Schervish, 2007) Let {Zi}∞i=1 be independently distributed with
densities {fi(·; θ)}∞i=1, with respect to a common σ-finite measure, where the parameter θ
belongs to an abstract measurable space Θ. The densities fi(·; θ) are assumed to be jointly
measurable. Let θ0 ∈ Θ and let Pθ0 stand for the joint distribution of {Zi}∞i=1 when θ0 is the
true value of θ. Let {Un}∞i=1 be a sequence of subsets of Θ. Let θ have prior Π on Θ. Define
Λi(θ0, θ) = log
fi(Zi; θ0)
fi(Zi; θ)
,
Ki(θ0, θ) = Eθ0(Λi(θ0, θ)),
Vi(θ0, θ) = Varθ0(Λi(θ0, θ)).
(A1) Prior positivity of neighborhoods.
Suppose that thee exists a set B with Π(B) > 0 such that
1.
∑∞
i=1
Vi(θ0,θ)
i2
<∞, ∀θ ∈ B,
2. For all  > 0, Π(B ∩ {θ : Ki(θ0, θ) <  for all i}) > 0.
(A2) Existence of tests
Suppose that there exist test functions {Φn}∞i=1, sets {Θn}∞i=1 and constants C1, C2, c1, c2 >
0 such that
1.
∑∞
i=1 Eθ0Φn <∞,
2. supθ∈UCn ∩Θn Eθ(1− Φn) ≤ C1e−c1n,
3. Π(ΘCn ) ≤ C2e−c2n.
Then
Π(θ ∈ UCn |Z1, . . . , Zn)→ 0 a.s. [Pθ0 ].
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